Barriers and perceived limitations to early treatment of hemophilia

Saxena, Kapil
May 2013
Journal of Blood Medicine;May2013, Vol. 4, p49
Academic Journal
Early treatment of bleeds in hemophilia patients, both with and without inhibitors, has been shown to be of immense benefit in the overall clinical outcome. Despite the advantages of treating the bleeding episodes early, significant barriers and limitations remain. The aim of this review is to highlight the various barriers and perceived limitations to early therapy of bleeding episodes, especially in patients who have developed inhibitors to factor VIII. The peer-reviewed literature was searched for articles on hemophilia patients, with and without inhibitors, and early treatment, to identify the barriers to early treatment and potential impact on patient outcomes. The most important barrier is the educational barrier, which involves lack of awareness among patients regarding the signs of a bleed, as well as importance of early therapy. It is also common for parents or caregivers of school-age children to exhibit inconvenience and scheduling barriers. Distance to the treatment center can also play a role here. Some patients experience financial barriers related to cost of clotting factor products, insurance coverage, or insurance caps and out-of-pocket costs. Rarely, there can also be problems related to venous access or home infusion. Lastly, multiple psychosocial barriers can prevent adherence to treatment regimens. Identification and addressing these individual barriers will result in improved compliance rates, prevent joint damage, be more cost-effective, and lead to better overall health of these patients.


Related Articles

  • Perioperatives Management bei Patienten mit Hämophilie. Lison, S.; Spannagl, M. // Anaesthesist;Jan2014, Vol. 63 Issue 1, p6 

    Hemophilia A and hemophilia B are X chromosome-linked congenital bleeding disorders caused by a deficiency or absence of activity of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B), which are graded in different degrees of severity (mild, moderate, severe). Depending on the...

  • Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A. Shin Young Hyun; Seon Yang Park; Soon Yong Lee; Hoon Kook; Sang Hoon Paik; In-Jin Jang; Kun Soo Lee // Yonsei Medical Journal;Jul2015, Vol. 56 Issue 4, p934 

    Purpose: Beroctocog alfa is a second generation recombinant factor VIII manufactured by removing the B-domain from factor VIII. This prospective clinical trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of beroctocog alfa in patients of ages ≥ 12 years previously...

  • factor VIII fraction (octocog alfa).  // Royal Society of Medicine: Medicines;2002, p240 

    This article presents information on the blood coagulation factor VIII fraction (octocog alfa). It is a preparation of recombinant human antihaemophilic factor VIII. It acts as a drug to reduce or stop bleeding, and is administered by intravenous infusion or injection to treat disorders in which...

  • Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea. Byung Suk Moon; Jun Seok Choi; Chur Woo You // Korean Journal of Pediatrics;Jul2013, Vol. 56 Issue 7, p291 

    Purpose: The aim of this study was to investigate prophylactic treatment effects in Korean patients with severe hemophilia A. Methods: A prospective study of 32 severe hemophilia A patients was conducted with the approval of the Institutional Review Board at the Eulji University Hospital. Two...

  • Haemophilia. Lawrence, Kingsley // GP: General Practitioner;4/27/2007, p30 

    The article presents information on the diagnosis and treatment of hemophilia. Hemophilia is characterized by spontaneous bleeding into joints and major muscle groups. The main principle of treatment of Hemophilia is to treat spontaneous bleeds early. Patients with low-titre antibodies may be...

  • Better blood. Marchant, Joanna; Boyce, Nell // New Scientist;03/11/2000, Vol. 165 Issue 2229, p7 

    Reports that an implant that treats the blood of hemophiliacs should free patients from the need for constant injections and the associated risk of diseases such as HIV. Details on an invention by Harvey Pollard et al of an implant for hemophiliacs which makes the missing blood factors VIII...

  • From battlefield to hospital: Researchers ponder broader role for drug designed to stop the bleeding. Byrd, Jonathan // Drug Formulary Review;Apr2007 Supplement, Vol. 23, p1 

    The article provides information on NovoSeven«, a blood derivative of recombinant factor VIIa which is derived from hamster cells and approved for uncontrolled bleeding episodes in hemophiliacs. Adverse effects of NovoSeven« include fever, hemorrhage, decreased fibrinogen, and...

  • factor VIIa (recombinant).  // Royal Society of Medicine: Medicines;2002, p240 

    This article presents information on the blood coagulation factor VIIa. Factor VIIa is a preparation of recombinant human antihaemophilic factor VII. It acts as a drug to reduce or stop bleeding and is used to treat disorders in which bleeding is prolonged and potentially dangerous, usually...

  • APPARATUS HOLDS PROMISE FOR HEMOPHILIACS. Moore, Amy Slugg // RN;Jun2000, Vol. 63 Issue 6, p104 

    Reports that a device that generates clotting proteins from factors already present in the blood may be used to treat hemophilia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics